Pharmaniaga is now a PN17 company.
The government-linked company last year struggled to sell Sinovac Covid-19 vaccines amounting to RM552.3 million and wrote down an Indonesian unit of RM50.3 million.
It has now been labelled financially distressed on Bursa Malaysia.
The government-linked company last year struggled to sell Sinovac Covid-19 vaccines amounting to RM552.3 million and wrote down an Indonesian unit of RM50.3 million.
It has now been labelled financially distressed on Bursa Malaysia.
Pharmaniaga’s parent is Boustead Holdings which in turn is controlled by armed forces fund Lembaga Tabung Angkatan Tentera.
A large impairment could impact Boustead.
A large impairment could impact Boustead.
Pharmaniaga posted a net loss of RM644. 39 million for 4Q22. This brings total losses for 2022 at RM607.31 million.
Loading suggestions...